Online inquiry

IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12360MR)

This product GTTS-WQ12360MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12360MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15680MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ3024MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ7884MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ15023MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ7298MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ6378MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ614MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ3768MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW